Table 4. Proportion of full-dose lenalidomide received, days treated and median dexamethasone dose, according to dose reduction.
|
Dose reduction |
|||
|---|---|---|---|
| ⩾12 Months (n=25) | <12 Months (n=39) | No dose reduction (n=52) | |
| Median proportion of lenalidomide dose received, % (25%, 75%)a | 72.2 (63.4, 84.0) | 50.5 (34.5, 63.8) | 90.4 (83.5, 98.4) |
| Median proportion of days treated, % (25%, 75%)b | 88.7 (79.2, 96.4) | 89.1 (82.2, 93.6) | 90.4 (83.5, 98.4) |
| Median dexamethasone dose, mg (25%, 75%)c | 40.0 (30.3, 40.0) | 40.0 (37.2, 40.0) | 36.3 (29.4, 40.0) |
| Proportion of dexamethasone dose received, %d | |||
| Year 1 (target 9.2 mg/day) | 87 (n=25) | 88 (n=39) | 96 (n=52) |
| Year 2 (target 5.7 mg/day) | 109 (n=25) | 114 (n=39) | 91 (n=52) |
| Year 3 (target 5.7 mg/day) | 56 (n=22) | 49 (n=19) | 86 (n=33) |
| Year 4 (target 5.7 mg/day) | 53 (n=15) | 46 (n=11) | 88 (n=23) |
a
Total target dose was 25 mg/day.
b
Total target days of treatment was 21 days per 28-day cycle.
c
Reflects dose on days of treatment. Per protocol patients received 40 mg/day dexamethasone for days 1–4, 9–12 and 17–20 for four cycles, and then 40 mg/day for days 1–4 for subsequent cycles.
d
Median target dose is calculated as total dose received/days on study.